136 related articles for article (PubMed ID: 311341)
21. The sensitivity to gamma-irradiation of the phases of the virus-host interaction: studies with strains of Semliki forest virus in mice.
Bradish CJ; Titmuss D; Fitzgeorge R
J Gen Virol; 1980 May; 48(1):39-51. PubMed ID: 7381435
[TBL] [Abstract][Full Text] [Related]
22. The effect of liposomal charge on the neutralizing antibody response against inactivated encephalomyocarditis and Semliki Forest viruses.
Kraaijeveld CA; Schilham M; Jansen J; Benaissa-Trouw B; Harmsen M; van Houte AJ; Snippe H
Clin Exp Immunol; 1984 Jun; 56(3):509-14. PubMed ID: 6086188
[TBL] [Abstract][Full Text] [Related]
23. Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis.
Amor S; Scallan MF; Morris MM; Dyson H; Fazakerley JK
J Gen Virol; 1996 Feb; 77 ( Pt 2 )():281-91. PubMed ID: 8627232
[TBL] [Abstract][Full Text] [Related]
24. Host defenses in experimental scrub typhus: role of cellular immunity in heterologous protection.
Shirai A; Catanzaro PJ; Phillips SM; Osterman JV
Infect Immun; 1976 Jul; 14(1):39-46. PubMed ID: 820646
[TBL] [Abstract][Full Text] [Related]
25. In vivo depletion of CD8+ T cells prevents lesions of demyelination in Semliki Forest virus infection.
Subak-Sharpe I; Dyson H; Fazakerley J
J Virol; 1993 Dec; 67(12):7629-33. PubMed ID: 7901429
[TBL] [Abstract][Full Text] [Related]
26. Immunogenicity and protective efficacy of Semliki forest virus replicon-based DNA vaccines encoding goatpox virus structural proteins.
Zheng M; Jin N; Liu Q; Huo X; Li Y; Hu B; Ma H; Zhu Z; Cong Y; Li X; Jin M; Zhu G
Virology; 2009 Aug; 391(1):33-43. PubMed ID: 19559453
[TBL] [Abstract][Full Text] [Related]
27. Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus.
Boere WA; Benaissa-Trouw BJ; Harmsen T; Erich T; Kraaijeveld CA; Snippe H
J Virol; 1985 May; 54(2):546-51. PubMed ID: 2985817
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant effects of dimethyl dioctadecyl ammonium bromide, complete Freund's adjuvant and aluminium hydroxide on neutralizing antibody, antibody-isotype and delayed-type hypersensitivity responses to Semliki Forest virus in mice.
Katz D; Lehrer S; Galan O; Lachmi BE; Cohen S
FEMS Microbiol Immunol; 1991 Nov; 3(6):305-20. PubMed ID: 1812932
[TBL] [Abstract][Full Text] [Related]
29. Studies on linear epitopes of Semliki Forest virus in protection studies against lethal challenge virus infection.
Truyen U; Kaaden OR
Zentralbl Veterinarmed B; 1991 Aug; 38(6):463-7. PubMed ID: 1719714
[TBL] [Abstract][Full Text] [Related]
30. Cell mediated immunity in experimental infection with Semliki forest virus in mice.
Likar M; Kovic M; Pustovrh B; Sok M
Acta Med Iugosl; 1975; 29(2):127-33. PubMed ID: 1169869
[No Abstract] [Full Text] [Related]
31. Immunization with recombinant Semliki Forest virus induces protection against influenza challenge in mice.
Berglund P; Fleeton MN; Smerdou C; Liljeström P
Vaccine; 1999 Feb; 17(5):497-507. PubMed ID: 10073729
[TBL] [Abstract][Full Text] [Related]
32. Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine.
Fleeton MN; Liljeström P; Sheahan BJ; Atkins GJ
J Gen Virol; 2000 Mar; 81(Pt 3):749-58. PubMed ID: 10675413
[TBL] [Abstract][Full Text] [Related]
33. Age-dependent and strain-related differences of virulence of Semliki Forest virus in mice.
Fleming P
J Gen Virol; 1977 Oct; 37(1):93-105. PubMed ID: 915485
[TBL] [Abstract][Full Text] [Related]
34. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.
Fleeton MN; Sheahan BJ; Gould EA; Atkins GJ; Liljestr M P
J Gen Virol; 1999 May; 80 ( Pt 5)():1189-1198. PubMed ID: 10355766
[TBL] [Abstract][Full Text] [Related]
35. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
Näslund TI; Uyttenhove C; Nordström EK; Colau D; Warnier G; Jondal M; Van den Eynde BJ; Liljeström P
J Immunol; 2007 Jun; 178(11):6761-9. PubMed ID: 17513723
[TBL] [Abstract][Full Text] [Related]
36. In vitro studies of cell-mediated immunity in an acute viral infection.
McFarland HF
J Immunol; 1974 Jul; 113(1):173-80. PubMed ID: 4598885
[No Abstract] [Full Text] [Related]
37. [Nonspecific host defence of neurotropic arbovirus infections].
Hofmann H
Zentralbl Bakteriol Orig A; 1973 Feb; 223(2):143-63. PubMed ID: 4145871
[No Abstract] [Full Text] [Related]
38. Effect of pregnancy on stimulation of alphavirus immunity in mice.
Milner AR; Marshall ID; Mullbacher A
J Virol; 1984 Apr; 50(1):73-6. PubMed ID: 6321802
[TBL] [Abstract][Full Text] [Related]
39. Influence of epitope polarity and adjuvants on the immunogenicity and efficacy of a synthetic peptide vaccine against Semliki Forest virus.
Fernández IM; Snijders A; Benaissa-Trouw BJ; Harmsen M; Snippe H; Kraaijeveld CA
J Virol; 1993 Oct; 67(10):5843-8. PubMed ID: 7690411
[TBL] [Abstract][Full Text] [Related]
40. Immunomodulation of host resistance to experimental viral infections in mice: effects of Corynebacterium acnes, Corynebacterium parvum, and Bacille calmette-guérin.
Glasgow LA; Fischbach J; Bryant SM; Kern ER
J Infect Dis; 1977 May; 135(5):763-70. PubMed ID: 192811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
